Diligence memo · auto-generated · as of July 2, 2026
Initial Therapeutics, Inc.
Initial Therapeutics, Inc. looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Initial Therapeutics, Inc. operates in Biotechnology, based in NEW YORK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Initial Therapeutics, Inc. has raised $3.8M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.8M on 2020-07-02.
Most recent recorded round closed around 2020-07-02.
Valuation (modeled)modeled
Provath models Initial Therapeutics, Inc. at approximately $169M (range $2.7M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.62× the median modeled value of Seed Biotechnology companies in 2019–2021 (186 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 6.0 yr ago; this sector typically re-raises about every 14 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 39% of Biotechnology peers (4293 compared).
Modeled value ranks above 69% of those peers.
Closest niche peers: Novo Biosciences, Inc., Entac Medical, Inc., ReGelTec, Inc., Korro Bio, Inc., TamuroBio Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.